The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus
Open accessAbstract
Personalized cancer medicine is based on the concept that targeted therapies are effective on subsets of patients whose tumors carry specific molecular alterations. Several mammalian target of rapamycin (mTOR) inhibitors are in preclinical or clinical trials for cancers, but the molecular basis of sensitivity or resistance to these inhibitors among patients is largely unknown. Here we have identified oncogenic variants of phosphoinositide-3-kinase, catalytic, alpha polypeptide (PIK3CA) and KRAS as determinants of response to the mTOR inhibitor everolimus. Human cancer cells carrying alterations in the PI3K pathway were responsive to everolimus, both in vitro and in vivo, except when KRAS mutations occurred concomitantly or were exogenously introduced. In human cancer cells with mutations in both PIK3CA and KRAS, genetic ablation of mutant KRAS reinstated response to the drug. Consistent with these data, PIK3CA mutant cells, but not KRAS mutant cells, displayed everolimus-sensitive translation. Importantly, in a cohort of metastatic cancer patients, the presence of oncogenic KRAS mutations was associated with lack of benefit after everolimus therapy. Thus, our results demonstrate that alterations in the KRAS and PIK3CA genes may represent biomarkers to optimize treatment of patients with mTOR inhibitors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Temsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell Carcinoma
Hudes, G., Carducci, M., Tomczak, P., Dutcher, J., Figlin, R., Kapoor, A., Staroslawska, E., Sosman, J., McDermott, D., Bodrogi, I., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa066838 · Cited by 3,647
Motzer, R. J., Escudier, B., Oudard, S., Hutson, T. E., Porta, C., Bracarda, S., Grünwald, V., Thompson, J. A., Figlin, R. A., Hollaender, N., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61039-9 · Cited by 3,019
mTOR Inhibition Induces Upstream Receptor Tyrosine Kinase Signaling and Activates Akt
O'Reilly, K. E., Rojo, F., She, Q.-B., Solit, D., Mills, G. B., Smith, D., Lane, H., Hofmann, F., Hicklin, D. J., Ludwig, D. L., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2925 · Cited by 2,561
Self-citationMolecular mechanisms of mTOR-mediated translational control
Ma, X. M., & Blenis, J. (2009) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2672 · Cited by 2,558
Exploiting the PI3K/AKT Pathway for Cancer Drug Discovery
Hennessy, B. T., Smith, D. L., Ram, P. T., Lu, Y., & Mills, G. B. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1902 · Cited by 2,185
Carracedo, A., Ma, L., Teruya-Feldstein, J., Rojo, F., Salmena, L., Alimonti, A., Egia, A., Sasaki, A. T., Thomas, G., Kozma, S. C., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci34739 · Cited by 1,381
Self-citationCurrent development of mTOR inhibitors as anticancer agents
Faivre, S., Kroemer, G., & Raymond, E. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2062 · Cited by 1,000
Moroni, M., Veronese, S., Benvenuti, S., Marrapese, G., Sartore-Bianchi, A., Di Nicolantonio, F., Gambacorta, M., Siena, S., & Bardelli, A. (2005) · The Lancet Oncology · doi:10.1016/s1470-2045(05)70102-9 · Cited by 941
Self-citationMutant PIK3CA promotes cell growth and invasion of human cancer cells.
Samuels, Y., Diaz, L. A., Schmidt-Kittler, O., Cummins, J. M., DeLong, L., Cheong, I., Rago, C., Huso, D. L., Lengauer, C., Kinzler, K. W., et al. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.05.014 · Cited by 915
Sun, S.-Y., Rosenberg, L. M., Wang, X., Zhou, Z., Yue, P., Fu, H., & Khuri, F. R. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0917 · Cited by 802
The RSK family of kinases: emerging roles in cellular signalling
Anjum, R., & Blenis, J. (2008) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2509 · Cited by 777
Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism
Wan, X., Harkavy, B., Shen, N., Grohar, P., & Helman, L. J. (2007) · Oncogene · doi:10.1038/sj.onc.1209990 · Cited by 755
Roux, P. P., Shahbazian, D., Vu, H., Holz, M. K., Cohen, M. S., Taunton, J., Sonenberg, N., & Blenis, J. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m700906200 · Cited by 702
Targeting the mTOR Signaling Network for Cancer Therapy
Meric-Bernstam, F., & Gonzalez-Angulo, A. M. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.0766 · Cited by 639
Altered Growth of Human Colon Cancer Cell Lines Disrupted at Activated Ki- ras
Shirasawa, S., Furuse, M., Yokoyama, N., & Sasazuki, T. (1993) · Science · doi:10.1126/science.8465203 · Cited by 620
Self-citationMutations in a signalling pathway
Parsons, D. W., Wang, T.-L., Samuels, Y., Bardelli, A., Cummins, J. M., DeLong, L., Silliman, N., Ptak, J., Szabo, S., Willson, J. K. V., et al. (2005) · Nature · doi:10.1038/436792a · Cited by 599
Self-citationPTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients
Frattini, M., Saletti, P., Romagnani, E., Martin, V, Molinari, F., Ghisletta, M., Camponovo, A., Etienne, L. L., Cavalli, F., & Mazzucchelli, L. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6604009 · Cited by 540 · cited 1×
“tions was performed and evaluated according to the literature (38).”
MethodSelf-citationScholl, C., Fröhling, S., Dunn, I. F., Schinzel, A. C., Barbie, D. A., Kim, S. Y., Silver, S. J., Tamayo, P., Wadlow, R. C., Ramaswamy, S., et al. (2009) · Cell · doi:10.1016/j.cell.2009.03.017 · Cited by 538
AKT-Independent Signaling Downstream of Oncogenic PIK3CA Mutations in Human Cancer
Vasudevan, K. M., Barbie, D. A., Davies, M. A., Rabinovsky, R., McNear, C. J., Kim, J. J., Hennessy, B. T., Tseng, H., Pochanard, P., Kim, S. Y., et al. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.04.012 · Cited by 524
mTOR Complex1–S6K1 signaling: at the crossroads of obesity, diabetes and cancer
Dann, S. G., Selvaraj, A., & Thomas, G. (2007) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2007.04.002 · Cited by 481
O'Donnell, A., Faivre, S., Burris, H. A., Rea, D., Papadimitrakopoulou, V., Shand, N., Lane, H. A., Hazell, K., Zoellner, U., Kovarik, J. M., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.0988 · Cited by 479
Tabernero, J., Rojo, F., Calvo, E., Burris, H., Judson, I., Hazell, K., Martinelli, E., Cajal, S. R. Y., Jones, S., Vidal, L., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.5482 · Cited by 474
Self-citationSiena, S., Sartore-Bianchi, A., Di Nicolantonio, F., Balfour, J., & Bardelli, A. (2009) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djp280 · Cited by 429
Self-citationOncogenic MAPK Signaling Stimulates mTORC1 Activity by Promoting RSK-Mediated Raptor Phosphorylation
Carrière, A., Cargnello, M., Julien, L.-A., Gao, H., Bonneil, É., Thibault, P., & Roux, P. P. (2008) · Current Biology · doi:10.1016/j.cub.2008.07.078 · Cited by 336
Novel Agents on the Horizon for Cancer Therapy
Ma, W. W., & Adjei, A. A. (2009) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20003 · Cited by 304
Yee, K. W. L., Zeng, Z., Konopleva, M., Verstovsek, S., Ravandi, F., Ferrajoli, A., Thomas, D., Wierda, W., Apostolidou, E., Albitar, M., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0764 · Cited by 285
Slomovitz, B. M., Lu, K. H., Johnston, T., Coleman, R. L., Munsell, M., Broaddus, R. R., Walker, C., Ramondetta, L. M., Burke, T. W., Gershenson, D. M., et al. (2010) · Cancer · doi:10.1002/cncr.25515 · Cited by 269
Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastoma
Reardon, D. A., Desjardins, A., Vredenburgh, J. J., Gururangan, S., Friedman, A. H., Herndon, J. E., Marcello, J., Norfleet, J. A., McLendon, R. E., Sampson, J. H., et al. (2010) · Journal of Neuro-Oncology · doi:10.1007/s11060-009-9950-0 · Cited by 232
Tanaka, C., O’Reilly, T., Kovarik, J. M., Shand, N., Hazell, K., Judson, I., Raymond, E., Zumstein-Mecker, S., Stephan, C., Boulay, A., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.1127 · Cited by 211
Hung, K. E., Maricevich, M. A., Richard, L. G., Chen, W. Y., Richardson, M. P., Kunin, A., Bronson, R. T., Mahmood, U., & Kucherlapati, R. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0908682107 · Cited by 198
Wang, X., Yue, P., Kim, Y. A., Fu, H., Khuri, F. R., & Sun, S. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-1522 · Cited by 167
Xing, D., & Oršulić, S. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0502256102 · Cited by 98
Nicolantonio, F. D., Arena, S., Gallicchio, M., Zecchin, D., Martini, M., Flonta, S. E., Stella, G. M., Lamba, S., Cancelliere, C., Russo, M., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0808757105 · Cited by 93
Self-citationAGC kinases regulate phosphorylation and activation of eukaryotic translation initiation factor 4B
van Gorp, A. G. M., van der Vos, K. E., Brenkman, A. B., Bremer, A., van den Broek, N. J. F., Zwartkruis, F. J. T., Hershey, J. W. B., Burgering, B. M. T., Calkhoven, C. F., & Coffer, P. J. (2008) · Oncogene · doi:10.1038/onc.2008.367 · Cited by 87
PKCβII modulates translation independently from mTOR and through RACK1
Grosso, S., Volta, V., Sala, L. A., Vietri, M., Marchisio, P. C., Dorit Ron, A., & Biffo, S. (2008) · Biochemical Journal · doi:10.1042/bj20080463 · Cited by 72
Self-citationSlomovitz, B. M., Lu, K. H., Johnston, T., Munsell, M. A., Ramondetta, L. M., Broaddus, R. R., Coleman, R. L., Walker, C., Gershenson, D. M., Burke, T. W., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.26.15_suppl.5502 · Cited by 39
Isogenic mutant human cells: A new tool for personalized cancer medicine
Nicolantonio, F. D., Arena, S., Gallicchio, M., & Bardelli, A. (2010) · Cell Cycle · doi:10.4161/cc.9.1.10474 · Cited by 10
Self-citation
Cited by
The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation
Mendoza, M. C., Er, E. E., & Blenis, J. (2011) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2011.03.006 · Cited by 1,817
Le Tourneau, C., Delord, J.-P., Gonçalves, A., Gavoille, C., Dubot, C., Isambert, N., Campone, M., Trédan, O., Massiani, M.-A., Mauborgne, C., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00188-6 · Cited by 1,137
Targeting the PI3K pathway in cancer: are we making headway?
Janku, F., Yap, T. A., & Meric-Bernstam, F. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2018.28 · Cited by 1,033
PI3K/AKT signaling pathway and cancer: An updated review
Martini, M., De Santis, M. C., Braccini, L., Gulluni, F., & Hirsch, E. (2014) · Annals of Medicine · doi:10.3109/07853890.2014.912836 · Cited by 1,020
Targeting mTOR for cancer therapy
Hua, H., Kong, Q., Zhang, H., Wang, J., Luo, T., & Jiang, Y. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0754-1 · Cited by 899
Metadata
- Authors
- Di Nicolantonio, F., Arena, S., Tabernero, J., Grosso, S., Molinari, F., Macarulla, T., Russo, M., Cancelliere, C., Zecchin, D., Mazzucchelli, L., Sasazuki, T., Shirasawa, S., Geuna, M., Frattini, M., Baselga, J., Gallicchio, M., Biffo, S., & Bardelli, A.
- Venue
- Journal of Clinical Investigation
- Published
- 2010-08-02
- Volume
- 120
- Issue
- 8
- Pages
- 2858-2866
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W2065703106
- Cited by
- 343
- References
- 38
- FWCI
- 14.89
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.